Lung Cancer Therapy Annual 7: 7th Edition (Hardback) book cover

Lung Cancer Therapy Annual 7

7th Edition

Edited by Rolf A. Stahel

CRC Press

176 pages

Purchasing Options:$ = USD
Hardback: 9781841848655
pub: 2012-08-13
eBook (VitalSource) : 9780429065798
pub: 2012-08-13
from $45.48

FREE Standard Shipping!


Highly Commended, BMA Medical Book Awards 2013

Oncology research and practice in lung cancer continues to develop rapidly. This latest edition of an acclaimed reference briefs the oncology community with a review of the recent literature, emphasizing the most significant therapeutic advances. The expert contributions ofLung Cancer Therapy Annual 7 offer an update of the impact that this information will have on the day-to-day management of the lung cancer patient.

New to the seventh edition are four new chapters on the treatment of non-small cell lung cancer (NSCLC) and a new chapter on thymoma. Additional topics include:

  • Oncogenic driver mutations
  • First line therapy of advanced non-small cell lung cancer without activating EGFR mutation
  • Second line therapy of non-small cell lung cancer
  • Adjunct and neoadjunct therapy of non-small cell lung cancer
  • Advances in surgery of lung cancer; advances in radiotherapy of lung cancer
  • Mesothelioma
  • Thymic tumors


"This is an excellent resource for beginners as well as advanced specialists in the field. The references are current to the year 2008 and the individual chapters are brief and complete and will give readers a solid foundation in the treatment of lung cancer to build upon." - K. P. Ravikrishnan, FRCP (C), FACP FCCP(William Beaumont Hospitals)

Table of Contents

Epidemiology of lung cancer

Menghua Tao and Paolo Boffetta

Prevention, early detection and screening

Giulia Veronesi


Christophe Dooms

Histo- and molecular pathology of lung cancer

A. Soltermann, S. Peters, and V. Tischler

Oncogenic driver mutations

Hiromichi Ebi and Tetsuya Mitsudomi

First-line therapy of advanced non-small cell lung cancer not harboring an activating EGFR mutation

Cesare Gridelli and Antonio Rossi

First-line therapy of advanced non-small cell lung cancer with activating EGFR mutations

Caicun Zhou

Second-line therapy of non-small cell lung cancer

David F. Heigener, Sabine Bohnet, and Martin Reck

Adjuvant and neoadjuvant therapy of non-small cell lung cancer

Alejandro Navarro Mendivil and Enriqueta Felip

Advances in surgery of lung cancer

Paul E. Van Schil, Jeroen M. Hendriks, Marjan Hertoghs, Patrick Lauwers, and Cliff K. Choong

Recent advances in radiotherapy for lung cancer

Dirk K. M. De Ruysscher and José S.A. Belderbos

Treatment of small cell lung cancer

Aleksandar Aleksic and Sanjay Popat


Emanuela Felley-Bosco and Isabelle Opitz

Thymic tumors

Enrico Ruffini, Pier Luigi Filosso, Paolo Lausi, and Alberto Oliaro

About the Editor

Rolf A. Stahel, M.D. is head of the Center for Lung and Thoracic Oncology and Senior Staff Physician at the Clinic of Oncology, University Hospital of Zürich as well as Titular Professor of Medicine at the University of Zürich, Switzerland. He is certified in Internal Medicine and Medical Oncology by both the American and Swiss Board. His major interest is thoracic oncology, including multidisciplinary treatment approaches, translational research, and targeted therapy.

Subject Categories

BISAC Subject Codes/Headings:
MEDICAL / Oncology
MEDICAL / Pulmonary & Thoracic Medicine